Cargando…

F176. CLINICAL CORRELATES OF CORTICAL STRUCTURE IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BEFORE AND AFTER SIX-WEEK TREATMENT WITH A DOPAMINE D2/3 RECEPTOR ANTAGONIST

BACKGROUND: Schizophrenia has been associated with changes in both cortical thickness and surface area, but antipsychotic exposure, illness progression, and substance use may confound the observations. We investigated cortical thickness and surface area, as well as mean curvature, before and after a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jessen, Kasper, Rostrup, Egill, Mandl, Rene C W, Nielsen, Mette Ø, Bak, Nikolaj, Fagerlund, Birgitte, Glenthøj, Birte Y, Ebdrup, Bjørn H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887483/
http://dx.doi.org/10.1093/schbul/sby017.707
_version_ 1783312313501089792
author Jessen, Kasper
Rostrup, Egill
Mandl, Rene C W
Nielsen, Mette Ø
Bak, Nikolaj
Fagerlund, Birgitte
Glenthøj, Birte Y
Ebdrup, Bjørn H
author_facet Jessen, Kasper
Rostrup, Egill
Mandl, Rene C W
Nielsen, Mette Ø
Bak, Nikolaj
Fagerlund, Birgitte
Glenthøj, Birte Y
Ebdrup, Bjørn H
author_sort Jessen, Kasper
collection PubMed
description BACKGROUND: Schizophrenia has been associated with changes in both cortical thickness and surface area, but antipsychotic exposure, illness progression, and substance use may confound the observations. We investigated cortical thickness and surface area, as well as mean curvature, before and after antipsychotic monotherapy with a relatively selective dopamine D2/3 antagonist (amisulpride), in antipsychotic-naïve schizophrenia patients. METHODS: Fifty-six patients and 59 matched healthy controls (HC) underwent T1-weighted 3T magnetic resonance imaging. Forty-one patients and 51 HCs were re-scanned. FreeSurfer-processed baseline values and symmetrized percentage changes (SPC) in cortical structures were analysed using univariate ANOVA. Clinical measures comprised psychopathology ratings, assessment of functioning, and tests of premorbid and current intelligence. RESULTS: At baseline, groups did not differ in cortical thickness or surface area, while left curvature was higher in patients (p=0.015). In the complete sample, a higher curvature was associated with lower premorbid- (p=0.009) and current intelligence (p<0.001). Also, a lower surface area was associated with lower premorbid intelligence (p=0.014) and, in patients, a higher PANSS total (p=0.037). Lifetime substance use was associated with reduced cortical thickness (p=0.043). After six weeks, groups did not differ in overall change in cortical structures. Amisulpride dose (275.0 mg/day) did not correlate with cortical structures (p>0.43). A decrease in cortical thickness SPC was associated with less symptom improvement (p=0.002) and increase in surface area SPC was associated with improvement in GAF (p=0.047). DISCUSSION: Our results indicate that schizophrenia may be associated with subtle aberrations in cortical structures and these changes appear clinically relevant. Mean curvature holds promise as a sensitive supplement to cortical thickness and surface area, to detect complex structural brain abnormalities.
format Online
Article
Text
id pubmed-5887483
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-58874832018-04-11 F176. CLINICAL CORRELATES OF CORTICAL STRUCTURE IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BEFORE AND AFTER SIX-WEEK TREATMENT WITH A DOPAMINE D2/3 RECEPTOR ANTAGONIST Jessen, Kasper Rostrup, Egill Mandl, Rene C W Nielsen, Mette Ø Bak, Nikolaj Fagerlund, Birgitte Glenthøj, Birte Y Ebdrup, Bjørn H Schizophr Bull Abstracts BACKGROUND: Schizophrenia has been associated with changes in both cortical thickness and surface area, but antipsychotic exposure, illness progression, and substance use may confound the observations. We investigated cortical thickness and surface area, as well as mean curvature, before and after antipsychotic monotherapy with a relatively selective dopamine D2/3 antagonist (amisulpride), in antipsychotic-naïve schizophrenia patients. METHODS: Fifty-six patients and 59 matched healthy controls (HC) underwent T1-weighted 3T magnetic resonance imaging. Forty-one patients and 51 HCs were re-scanned. FreeSurfer-processed baseline values and symmetrized percentage changes (SPC) in cortical structures were analysed using univariate ANOVA. Clinical measures comprised psychopathology ratings, assessment of functioning, and tests of premorbid and current intelligence. RESULTS: At baseline, groups did not differ in cortical thickness or surface area, while left curvature was higher in patients (p=0.015). In the complete sample, a higher curvature was associated with lower premorbid- (p=0.009) and current intelligence (p<0.001). Also, a lower surface area was associated with lower premorbid intelligence (p=0.014) and, in patients, a higher PANSS total (p=0.037). Lifetime substance use was associated with reduced cortical thickness (p=0.043). After six weeks, groups did not differ in overall change in cortical structures. Amisulpride dose (275.0 mg/day) did not correlate with cortical structures (p>0.43). A decrease in cortical thickness SPC was associated with less symptom improvement (p=0.002) and increase in surface area SPC was associated with improvement in GAF (p=0.047). DISCUSSION: Our results indicate that schizophrenia may be associated with subtle aberrations in cortical structures and these changes appear clinically relevant. Mean curvature holds promise as a sensitive supplement to cortical thickness and surface area, to detect complex structural brain abnormalities. Oxford University Press 2018-04 2018-04-01 /pmc/articles/PMC5887483/ http://dx.doi.org/10.1093/schbul/sby017.707 Text en © Maryland Psychiatric Research Center 2018. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstracts
Jessen, Kasper
Rostrup, Egill
Mandl, Rene C W
Nielsen, Mette Ø
Bak, Nikolaj
Fagerlund, Birgitte
Glenthøj, Birte Y
Ebdrup, Bjørn H
F176. CLINICAL CORRELATES OF CORTICAL STRUCTURE IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BEFORE AND AFTER SIX-WEEK TREATMENT WITH A DOPAMINE D2/3 RECEPTOR ANTAGONIST
title F176. CLINICAL CORRELATES OF CORTICAL STRUCTURE IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BEFORE AND AFTER SIX-WEEK TREATMENT WITH A DOPAMINE D2/3 RECEPTOR ANTAGONIST
title_full F176. CLINICAL CORRELATES OF CORTICAL STRUCTURE IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BEFORE AND AFTER SIX-WEEK TREATMENT WITH A DOPAMINE D2/3 RECEPTOR ANTAGONIST
title_fullStr F176. CLINICAL CORRELATES OF CORTICAL STRUCTURE IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BEFORE AND AFTER SIX-WEEK TREATMENT WITH A DOPAMINE D2/3 RECEPTOR ANTAGONIST
title_full_unstemmed F176. CLINICAL CORRELATES OF CORTICAL STRUCTURE IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BEFORE AND AFTER SIX-WEEK TREATMENT WITH A DOPAMINE D2/3 RECEPTOR ANTAGONIST
title_short F176. CLINICAL CORRELATES OF CORTICAL STRUCTURE IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BEFORE AND AFTER SIX-WEEK TREATMENT WITH A DOPAMINE D2/3 RECEPTOR ANTAGONIST
title_sort f176. clinical correlates of cortical structure in antipsychotic-naïve schizophrenia patients before and after six-week treatment with a dopamine d2/3 receptor antagonist
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887483/
http://dx.doi.org/10.1093/schbul/sby017.707
work_keys_str_mv AT jessenkasper f176clinicalcorrelatesofcorticalstructureinantipsychoticnaiveschizophreniapatientsbeforeandaftersixweektreatmentwithadopamined23receptorantagonist
AT rostrupegill f176clinicalcorrelatesofcorticalstructureinantipsychoticnaiveschizophreniapatientsbeforeandaftersixweektreatmentwithadopamined23receptorantagonist
AT mandlrenecw f176clinicalcorrelatesofcorticalstructureinantipsychoticnaiveschizophreniapatientsbeforeandaftersixweektreatmentwithadopamined23receptorantagonist
AT nielsenmetteø f176clinicalcorrelatesofcorticalstructureinantipsychoticnaiveschizophreniapatientsbeforeandaftersixweektreatmentwithadopamined23receptorantagonist
AT baknikolaj f176clinicalcorrelatesofcorticalstructureinantipsychoticnaiveschizophreniapatientsbeforeandaftersixweektreatmentwithadopamined23receptorantagonist
AT fagerlundbirgitte f176clinicalcorrelatesofcorticalstructureinantipsychoticnaiveschizophreniapatientsbeforeandaftersixweektreatmentwithadopamined23receptorantagonist
AT glenthøjbirtey f176clinicalcorrelatesofcorticalstructureinantipsychoticnaiveschizophreniapatientsbeforeandaftersixweektreatmentwithadopamined23receptorantagonist
AT ebdrupbjørnh f176clinicalcorrelatesofcorticalstructureinantipsychoticnaiveschizophreniapatientsbeforeandaftersixweektreatmentwithadopamined23receptorantagonist